Memory Disorders
Drug research and approvals for memory Disorders: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 232 studies of memory Disorders are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 232
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 232 recruiting on ClinicalTrials.gov ↗- Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in SchizophreniaNCT07592169 · Phase 2 · University of California, San Diego · starts Nov 5, 2026
- Eye Movement Intervention With Different Memory Reactivation Procedures for Intrusive Traumatic MemoriesNCT07767396 · Not applicable · Shaanxi Normal University · starts Oct 30, 2026
- tACS for Working Memory in SchizophreniaNCT07701343 · Not applicable · Central South University · starts Oct 26, 2026
- Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Ductal AdenocarcinomaNCT07828236 · Phase 1 · Loki Therapeutics, Inc. · starts Oct 15, 2026
- Choose Myself (Before) Losing MyselfNCT07846566 · Not applicable · The Cleveland Clinic · starts Oct 9, 2026
- Retraining Neural Pathways Improves Cognitive Skills After A Mild Traumatic Brain InjuryNCT03655782 · Not applicable · Perception Dynamics Institute · starts Oct 5, 2026
- SAINT® Therapy for Memory Problems in Older Adults With Treatment-Resistant DepressionNCT07876908 · Not applicable · BrainHealth Solutions, Inc. · starts Oct 1, 2026
- A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's DiseaseNCT07254234 · Not reported · Eli Lilly and Company · starts Sep 23, 2026
- Percepta for Cognitive OptimizationNCT07612449 · Not applicable · Cerebrum DAO Association · starts Sep 14, 2026
- A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory…NCT07788118 · Phase 1 / Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts Sep 1, 2026
Drug Pipeline
5 in phase 3, 6 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Celecoxib
- Phase 3 Cyclooxygenase-2 inhibitor
- Progesterone
- Phase 3 Progesterone receptor agonist
- Estrogens, conjugated
- Phase 3 Estrogen receptor agonist
- Ginkgo
- Phase 3
- Estrogen
- Phase 3
- Albuterol
- Phase 2 Beta-2 adrenergic receptor agonist
- Vilazodone
- Phase 2 Serotonin transporter inhibitor
- Cinacalcet
- Phase 2 Calcium sensing receptor positive allosteric modulator
- Ispronicline
- Phase 2 Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
- HT-0712
- Phase 2 Phosphodiesterase 4 inhibitor
- Tricaprilin
- Phase 2
- Nicotine
- Phase 1 Neuronal acetylcholine receptor; alpha4/beta2 agonist
- Minocycline
- Phase 1 Bacterial 70S ribosome inhibitor
- Leteprinim
- Phase 1
How Its Trials Ended
201 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 40 whose ending is known, 35% met their primary endpoint, 25% missed it and 40% stopped early.
- Completed, result not reported9447%
- Ongoing4321%
- Status unknown2412%
- Met its primary endpoint147%
- Missed its primary endpoint105%
- Stopped: other or unclear94%
- Stopped: enrollment or feasibility73%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA